Tarix Orphan LLCCambridge, MAMedia contact: Joan KureczkaJoan@kureczka-martin.com (PRNewsFoto/Tarix Pharmaceuticals)

Tarix Orphan

Tarix Orphan is a private biopharmaceutical company headquartered in Cambridge, MA. Tarix Orphan is developing TXA127 for rare neuromuscular and connective tissue diseases. Tarix Orphan has broad IP protection for TXA127 and Orphan Drug Designations (ODDs) have been granted for DMD LGMD and DEB in the U.S., and for DMD in Europe. Tarix Orphan aims to initiate a clinical trials for both DMD and DEB in early 2018 and has an active IND for a Phase II trial in DMD, as well as Fast Track designation for DMD.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.tarixorphan.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
United States
Email
Contact Number
+1 617-827-6824

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]